Aprepitant 43% Pellets
Aprepitant 43% WW Pellets – NK1 Antagonist Pellets for Antiemetic Formulation Programs. Rraynex Aprepitant WW Pellets are developed as a 43% variant of the Aprepitant platform, providing a defined drug load for antiemetic and NK1 antagonist formulations requiring immediate-release multiparticulate behavior.
Product overview
The 43% WW variant is differentiated from the base Aprepitant pellet presentation by its specific strength, supporting distinct pharmaceutical development programs. Rraynex focuses on controlled pellet characteristics, flow and capsule filling performance. Technical specifications are available upon request.
Key characteristics
- Distinct 43% WW variant within the Aprepitant platform.
- Controlled pellet characteristics for capsule filling.
- Suitable for antiemetic pharmaceutical development.
- Technical support for formulation optimization and commercial supply.
Product specifications
- Product
- Aprepitant 43% Pellets
- Form
- Pellets
- Therapeutic category
- Neurokinin-1 Antagonist
- Strength
- 43%
- Grade
- IP / BP / USP / EP
- Pack size
- 25/50 kg
- Site certifications
- WHO-GMP, ISO 9001, ISO 14001
Detailed specifications, COA and technical documentation are shared on request.
Supply and enquiries
Rraynex supplies Aprepitant 43% Pellets to pharmaceutical manufacturers, formulation developers and CDMOs in 25/50 kg packs with batch traceability. Send your quantity, grade and documentation needs through the enquiry form and the commercial team will reply with specifications and a quotation. Rraynex is a B2B supplier and does not sell to consumers.
Send product enquiry Browse all pellets Manufacturing capabilities
Other Aprepitant products from Rraynex
- Aprepitant — Pellets